Shares of uniQure (NASDAQ: QURE) were down more than 11% as of 1:06 p.m. on Tuesday after the gene-therapy company announced that the Food and Drug Administration (FDA) had cleared its investigational new drug (IND) application for AMT-260, a treatment for refractory mesial temporal lobe epilepsy (MTLE). The disease is a chronic neurologic disorder, considered the most common form of focal epilepsy (which affects one side of the brain). At one point on Tuesday morning, the stock fell to a 52-week low of $7.40.
Clinical trial initiation expected in the fourth quarter of 2023LEXINGTON, Mass. and AMSTERDAM, Sept. 05, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for AMT-260, the Company’s gene therapy candidate for refractory mesial temporal lobe epilepsy (MTLE). AMT-260
S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P 100, S&P MidCap 400 and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 18, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more repres